论文部分内容阅读
目的观察联合应用沙利度胺(反应停)对难治性或不能耐受化疗的恶性血液病患者的治疗效果。方法对20例常规治疗方案不能缓解或无法耐受常规治疗的恶性血液病患者加用沙利度胺。结果MDS治疗有效率66.7%,AML治疗有效率50%,MPD治疗有效率70%。结论联合应用沙利度胺可提高难治性或不能耐受化疗的恶性血液病的疗效。
Objective To observe the therapeutic effect of combined thalidomide (response stop) on patients with hematologic malignancies refractory or refractory to chemotherapy. Methods Thalidomide was given to 20 patients with hematologic malignancies who could not be relieved or unable to tolerate conventional treatment. Results The effective rate of MDS was 66.7%, that of AML was 50%, and that of MPD was 70%. Conclusion The combination of thalidomide can improve the curative effect of hematologic malignancy refractory or refractory to chemotherapy.